Pharmacotherapy in pain management and the safe prescribing of opioids

Overview

Opioid pharmacotherapy for pain follows a stepped approach matched to pain severity and type, with current guidance (2022 CDC Clinical Practice Guideline) emphasising that opioids are not first-line therapy for most chronic non-cancer pain, reserved instead for situations where benefits are expected to outweigh risks after non-opioid approaches have been optimised
Remains central to acute severe pain, cancer pain, and palliative/end-of-life pain management, though chronic non-cancer pain prescribing has shifted substantially toward more conservative, risk-stratified use given the opioid-related harm and dependence burden observed over the past two decades

Opioids act via mu-opioid receptor agonism, providing effective analgesia but with dose-dependent respiratory depression risk, tolerance development with continued use, and physical dependence - these mechanism-based properties explain both their efficacy and their characteristic risk profile requiring careful prescribing practice

Risk assessment before initiation (personal/family substance use history, mental health comorbidity, concurrent sedative use) informs appropriate caution and monitoring intensity
Lowest effective dose for the shortest duration necessary is current guidance for opioid-naive patients starting therapy for acute, subacute, or chronic pain, with structured review of benefit and risk within 1-4 weeks of initiation or dose escalation

Acute/cancer/palliative pain: opioids remain an appropriate, often first-line option matched to pain severity
Chronic non-cancer pain: non-opioid pharmacological and non-pharmacological approaches should be optimised first, with opioids reserved for situations where the expected benefit outweighs risk after this optimisation, not as a default first-line approach
Regular reassessment of ongoing benefit vs risk/harm for any patient on long-term opioid therapy, with a clear plan for tapering if benefit is not clearly demonstrated

2022 CDC guideline shift away from opioids as default chronic pain therapy, combined opioid-benzodiazepine prescribing risk (see ), opioid tolerance and dependence development, tapering approach for long-term opioid therapy not providing clear benefit
Current guidance explicitly states that opioids are not first-line therapy for chronic pain outside of active cancer treatment, palliative care, and end-of-life care - this represents a genuine, significant shift from older prescribing patterns, and non-opioid approaches should be optimised first for chronic non-cancer pain before opioid therapy is considered

4 more sections, plus exam facts

Premium unlocks every note across every specialty, and the full exam fact library behind it.